

Cytox welcomes Aduhelm

First therapy to treat causes of Alzheimer's – but who may benefit most?

Aduhelm (aducanumab) is the first approved therapy to treat the underlying causes of Alzheimer's disease. Dr. Richard Pither, CEO of Cytox said: "As Aduhelm has maximal efficacy in the early stages of AD, it has never been more important to understand the risk of Alzheimer's disease and to seek early interventions. These can be drug interventions or lifestyle changes."

The Cytox *genoSCORE*™ test, available in Europe and coming soon to the US, can identify individuals most at risk of cognitive decline due to Alzheimer's disease decades before any symptoms arise. The test uses a simple saliva sample, and is suitable for use in adults over 18 years.

Physicians assessing new patients, with cognitive complaints or concerns about family history of Alzheimer's, can use the *genoSCORE* test prior to invasive cerebrospinal fluid (CSF) testing or

expensive scanning, to better understand their patients' future risk of cognitive decline due to Alzheimer's disease. The read-out from the test helps guide future disease management approaches, including both therapeutic intervention and lifestyle changes (see "Taking Control of Brain Health").

The test is for physician use only; if you or your patients are interested in finding out more please visit the web portal: www.genoscore-lab.com

The *genoSCORE* test also has applications during the patient recruitment phase of clinical studies, enabling the selection of those individuals most likely to experience cognitive decline over the period of the study. With cohorts of patients enriched in this manner, it can increase the probability of observing efficacy with investigational new drugs. For further information please contact: support@cytoxgroup.com

Taking Control of Brain Health



For individuals with cognitive complaints or concerns there is a new genetic test, available through your physician, which can provide insight into your risk of developing Alzheimer's disease in the future. With this knowledge an individual can discuss, with their physician, the actions that can be taken to mitigate the risks of the onset and development of Alzheimer's disease symptoms

Cytox partners with Vanguard and IBX to provide new test

Cytox has established partnerships with two US-based organizations to bring the new *genoSCORE*-powered test to physicians and their patients. Driving the medical education and customer relations in the US, Vanguard Pharma is organizing a series of events and meetings. If you are interested in attending such an event to hear more about the *genoSCORE* test please contact: Erica Jalil alzheimers@vanguardpharma.com

Alongside Vanguard, Cytox will also be working with Infinity Biologix (IBX) to provide

genoSCORE as an IBX laboratory developed test in the US and Canada. IBX will receive and process all patient samples, and physicians will be able to order tests for patients and receive results through the dedicated web portal.

The test will be available to physicians in the coming months, and it is possible to pre-register interest through the web portal: www.genoscore-lab.com/register



AAIC conference posters – first patient experiences

At this year's AAIC conference, Cytox will be presenting two posters. Firstly a case study on the patient-experiences from patients using the European version of the test, *genoSCORE*-LAB.

The second poster assesses *genoSCORE* and PACC scores in ADNI study participants, and concludes that *genoSCORE* identify individuals at higher risk of future cognitive decline before symptoms are apparent.